Artisan Partners Limited Partnership increased its holdings in shares of Glaukos Corporation (NYSE:GKOS) by 35.1% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 457,383 shares of the medical instruments supplier’s stock after purchasing an additional 118,922 shares during the quarter. Artisan Partners Limited Partnership owned 1.32% of Glaukos worth $15,094,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Ameritas Investment Partners Inc. increased its position in Glaukos by 93.1% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,514 shares of the medical instruments supplier’s stock worth $104,000 after purchasing an additional 1,212 shares in the last quarter. BNP Paribas Arbitrage SA grew its position in Glaukos by 740.6% in the second quarter. BNP Paribas Arbitrage SA now owns 3,539 shares of the medical instruments supplier’s stock valued at $147,000 after acquiring an additional 3,118 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Glaukos in the second quarter valued at approximately $262,000. UBS Asset Management Americas Inc. acquired a new stake in Glaukos in the second quarter valued at approximately $274,000. Finally, Legal & General Group Plc grew its position in Glaukos by 77.6% in the second quarter. Legal & General Group Plc now owns 7,240 shares of the medical instruments supplier’s stock valued at $299,000 after acquiring an additional 3,164 shares in the last quarter. 99.23% of the stock is owned by hedge funds and other institutional investors.

GKOS has been the subject of several recent research reports. Stifel Nicolaus reaffirmed a “buy” rating on shares of Glaukos in a research report on Thursday, September 14th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Glaukos in a research report on Friday, September 15th. BidaskClub raised shares of Glaukos from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Glaukos in a research report on Tuesday, November 7th. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $54.00 price objective on shares of Glaukos in a research report on Friday, September 1st. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Glaukos presently has an average rating of “Buy” and a consensus target price of $46.57.

Shares of Glaukos Corporation (GKOS) opened at $25.87 on Tuesday. Glaukos Corporation has a 1 year low of $23.44 and a 1 year high of $52.49. The stock has a market cap of $894.21 and a P/E ratio of 219.75.

Glaukos (NYSE:GKOS) last released its earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.04 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.06. The company had revenue of $40.41 million during the quarter, compared to analysts’ expectations of $38.69 million. Glaukos had a positive return on equity of 3.50% and a negative net margin of 0.64%. The business’s revenue was up 36.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.03 EPS. research analysts predict that Glaukos Corporation will post -0.03 earnings per share for the current fiscal year.

In other news, CEO Thomas William Burns sold 73,788 shares of the stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $41.36, for a total transaction of $3,051,871.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Joseph E. Gilliam bought 2,100 shares of Glaukos stock in a transaction dated Wednesday, November 22nd. The shares were acquired at an average price of $23.84 per share, with a total value of $50,064.00. Following the completion of the purchase, the chief financial officer now owns 102,100 shares in the company, valued at approximately $2,434,064. The disclosure for this purchase can be found here. Corporate insiders own 16.40% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Glaukos Corporation (GKOS) Shares Bought by Artisan Partners Limited Partnership” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/12/05/glaukos-corporation-gkos-shares-bought-by-artisan-partners-limited-partnership.html.

About Glaukos

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Receive News & Stock Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related stocks with our FREE daily email newsletter.